Literature DB >> 22360618

Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.

Kazuaki Chikamatsu1, Koichi Sakakura, Minoru Toyoda, Katsumasa Takahashi, Takanori Yamamoto, Keisuke Masuyama.   

Abstract

Myeloid-derived suppressor cells (MDSC) represent a heterogeneous population and have the potential to suppress immune responses via diverse mechanisms. In recent studies, a new subset of MDSC was identified by the markers CD14(+) and HLA-DR(-) in the peripheral blood from cancer patients. In this study, we investigated the proportions and characteristics of CD14(+) HLA-DR(-) cells in patients with squamous cell carcinoma of the head and neck (SCCHN). As expected, the percentage of CD14(+) HLA-DR(-) cells was significantly elevated in patients relative to healthy donors and the sorted CD14(+) HLA-DR(-) cells were able to suppress effectively both the proliferation and IFN-γ production of anti-CD3/anti-CD28 stimulated T cells, suggesting that CD14(+) HLA-DR(-) cells in patients with SCCHN contribute to the immune suppressive status. Furthermore, CD14(+) HLA-DR(-) cells revealed a higher level of CD86 and PD-L1 expression and transforming growth factor (TGF)-β production than CD14(+) HLA-DR(+) cells. Addition of anti-CD86 mAb, anti-PD-L1 mAb and anti-TGF-β mAb partially restored T-cell proliferation and IFN-γ production, respectively, indicating that the suppressive effects of CD14(+) HLA-DR(-) cells appear to be mediated by various molecules, including coinhibitory molecules and cytokines. Our data suggest that CD14(+) HLA-DR(-) cells act as potent immunosuppressive cells and particularly contribute to tumor escape from the host immune system in patients with SCCHN.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360618      PMCID: PMC7685071          DOI: 10.1111/j.1349-7006.2012.02248.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  29 in total

1.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

Authors:  Arnold H Zea; Paulo C Rodriguez; Michael B Atkins; Claudia Hernandez; Sabina Signoretti; Jovanny Zabaleta; David McDermott; David Quiceno; Amanda Youmans; Anne O'Neill; James Mier; Augusto C Ochoa
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

Review 2.  Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact.

Authors:  James E Talmadge
Journal:  Semin Cancer Biol       Date:  2010-12-09       Impact factor: 15.707

3.  Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer.

Authors:  M R Young; M A Wright; Y Lozano; J P Matthews; J Benefield; M M Prechel
Journal:  Int J Cancer       Date:  1996-07-29       Impact factor: 7.396

4.  Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

Authors:  B Almand; J I Clark; E Nikitina; J van Beynen; N R English; S C Knight; D P Carbone; D I Gabrilovich
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

Review 5.  Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2010-04-23       Impact factor: 6.968

6.  Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

Authors:  Paolo Serafini; Stephanie Mgebroff; Kimberly Noonan; Ivan Borrello
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

7.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.

Authors:  A S Pak; M A Wright; J P Matthews; S L Collins; G J Petruzzelli; M R Young
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

Review 8.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

9.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

Review 10.  The B7 family of immune-regulatory ligands.

Authors:  Mary Collins; Vincent Ling; Beatriz M Carreno
Journal:  Genome Biol       Date:  2005-05-31       Impact factor: 13.583

View more
  43 in total

1.  Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes.

Authors:  Sílvia Casacuberta-Serra; Marta Parés; Arantxa Golbano; Elisabet Coves; Carmen Espejo; Jordi Barquinero
Journal:  Immunol Cell Biol       Date:  2017-01-21       Impact factor: 5.126

2.  [Immunotherapy of head and neck cancer. Current developments].

Authors:  P J Schuler; T K Hoffmann; T C Gauler; C Bergmann; S Brandau; S Lang
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

3.  Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.

Authors:  Shigehisa Kitano; Michael A Postow; Carly G K Ziegler; Deborah Kuk; Katherine S Panageas; Czrina Cortez; Teresa Rasalan; Mathew Adamow; Jianda Yuan; Philip Wong; Gregoire Altan-Bonnet; Jedd D Wolchok; Alexander M Lesokhin
Journal:  Cancer Immunol Res       Date:  2014-05-20       Impact factor: 11.151

4.  Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.

Authors:  Sarah Greene; Yvette Robbins; Wojciech K Mydlarz; Angel P Huynh; Nicole C Schmitt; Jay Friedman; Lucas A Horn; Claudia Palena; Jeffrey Schlom; Dean Y Maeda; John A Zebala; Paul E Clavijo; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

Review 5.  A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.

Authors:  Christopher Shipp; Lisa Speigl; Nicole Janssen; Alexander Martens; Graham Pawelec
Journal:  Cell Mol Life Sci       Date:  2016-05-28       Impact factor: 9.261

Review 6.  Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.

Authors:  Michelle N Messmer; Colleen S Netherby; Debarati Banik; Scott I Abrams
Journal:  Cancer Immunol Immunother       Date:  2014-11-29       Impact factor: 6.968

7.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.

Authors:  David Vasquez-Dunddel; Fan Pan; Qi Zeng; Mikhail Gorbounov; Emilia Albesiano; Juan Fu; Richard L Blosser; Ada J Tam; Tullia Bruno; Hao Zhang; Drew Pardoll; Young Kim
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

8.  Recent Advances in Head and Neck Tumor Microenvironment-Based Therapy.

Authors:  Muzafar A Macha; Nissar A Wani; Rais A Ganai; Ajaz A Bhat; Abid Hamid; Sheema Hashem; Mohammad Haris; Sham S Chauhan; Mohammad A Zargar; Surinder K Batra
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.

Authors:  Rania H Younis; Kyu Lee Han; Tonya J Webb
Journal:  J Immunol       Date:  2016-01-06       Impact factor: 5.422

10.  CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma.

Authors:  Takanobu Motoshima; Yoshihiro Komohara; Hasita Horlad; Hirotake Tsukamoto; Mitsugu Fujita; Yoichi Saito; Kenichiro Tanoue; Yutaka Kasejima; Yutaka Sugiyama; Yoshiaki Kawano; Yasuharu Nishimura; Motohiro Takeya; Masatoshi Eto
Journal:  Oncol Lett       Date:  2016-01-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.